Evaluation of Real-Life Investigational Use of Enoximone in Asthma, the Third Step in Drug Repurposing: A Preliminary Report.

Published in: Canadian respiratory journal (2021)

The evaluation shows that PDE3-inhibitor enoximone is a viable alternative for or addition to current asthma therapeutics, as both add-on and stand-alone, considerably reducing the use of LABAs/SABAs/ICS, with no or negligible side effects. Additional studies are advisable.

Keyphrases

chronic obstructive pulmonary disease
lung function
allergic rhinitis
small molecule
randomized controlled trial
clinical trial
case control
phase ii
adverse drug
clinical evaluation